8-K: Silence Therapeutics Divesiran Data Shows Promise in PV

Silence Therapeutics presented follow-up data from its Phase 1 SANRECO study of divesiran for polycythemia vera, highlighting durable efficacy and quality-of-life improvements.

Summary

• Silence Therapeutics presented new data from the Phase 1 SANRECO study of divesiran, a siRNA therapy for polycythemia vera (PV), at the European Hematology Association (EHA) 2026 Annual Congress.
• The data showed improvements in PV-related symptoms and quality-of-life, in addition to previously reported reductions in phlebotomy use.
• Follow-up analyses indicated that the reductions in phlebotomy use persisted well beyond the final dose of divesiran.
• The Phase 2 SANRECO study, evaluating Q6W and Q12W dosing regimens, is on track to report topline results in August 2026.
• Divesiran was generally well-tolerated, with most treatment-emergent adverse events being mild and transient injection-site reactions.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, with encouraging follow-up data reinforcing the potential of divesiran and a clear near-term catalyst with the upcoming Phase 2 results.

Positives

• Substantial reductions in phlebotomy use were observed, persisting well beyond the final dose, with a median time to first phlebotomy of 287 days among 14 patients with further follow-up.
• Improvements in MPN-10 total symptom scores were noted from baseline through Week 34, suggesting potential improvements in disease-related symptoms and overall quality of life.
• Divesiran demonstrated a favorable safety profile, being well-tolerated with no dose-limiting toxicities observed.
• The most common treatment-emergent adverse events were mild and transient injection-site reactions, with no treatment-related serious adverse events or discontinuations reported.
• The Phase 2 SANRECO study is on track for topline results in August 2026, providing a near-term catalyst.

Negatives

• The Phase 1 study included patients classified as uncontrolled at baseline with HCT levels greater than 45%, and all 5 phlebotomies during the active treatment period occurred in these patients.
• While generally well-tolerated, injection-site reactions were the most common adverse events.

Risks

• The company's ability to obtain necessary capital to fund its clinical programs.
• The early stages of clinical development for its product candidates.
• The ability to obtain regulatory approval and successfully commercialize its product candidates.
• Potential undesirable side effects or other properties of its product candidates.
• Reliance on third-party suppliers and manufacturers.
• Outcomes of any future collaboration agreements.
• The ability to adequately maintain intellectual property rights for its product candidates.

Future Outlook

Topline results from the Phase 2 SANRECO study, evaluating Q6W and Q12W dosing regimens in patients with PV, are expected in August 2026. The company is advancing its pipeline with a focus on areas of high unmet medical need.

Management Comments

• "Data presented at EHA continue to reinforce divesiran's potential to transform the treatment paradigm for patients with polycythemia vera."
• "In Phase 1, we observed sustained hematocrit control, symptom improvement, and robust and durable reductions in phlebotomy burden, which persisted after the final dose."
• "These findings further support the potential for less frequent dosing, including the Q12W regimen being evaluated in our ongoing Phase 2 SANRECO study, and we look forward to reporting topline results in August 2026."

Industry Context

StockSavvy.ai notes that the presentation of follow-up and quality-of-life data for divesiran at EHA 2026 is a positive step for Silence Therapeutics, reinforcing the potential of their siRNA technology in hematology. The persistence of efficacy signals beyond the treatment period is particularly encouraging for a chronic condition like PV, and the upcoming Phase 2 results will be crucial for further validation.

Stakeholder Impact

• Shareholders: Positive impact expected from promising clinical data and upcoming Phase 2 results, potentially increasing the company's valuation.
• Patients with Polycythemia Vera: Potential for a new, effective, and potentially less burdensome treatment option with durable effects.
• Healthcare Providers: May gain a new therapeutic option to manage PV symptoms and reduce phlebotomy requirements.

Next Steps

• Report topline results from the Phase 2 SANRECO study in August 2026.
• Continue clinical development of divesiran.

Key Dates

Recommendation

The data presented is encouraging and supports the continued development of divesiran, with a near-term catalyst in the upcoming Phase 2 results. However, the therapy is still in clinical development, and regulatory approval and commercialization remain significant hurdles. Therefore, a 'hold' recommendation is appropriate pending further data and de-risking events.

Keywords

Polycythemia Vera, Divesiran, siRNA, Silence Therapeutics, Hematology, Clinical Trial, TMPRSS6, EHA 2026